论文信息 - NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo. - 字舞流文

NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.

C. Denkert | J. Costantino | C. Geyer | N. Wolmark | S. Loibl | E. Mamounas | C. Jackisch | P. Cortazar | P. Rastogi | Namrata Vijayvergia | S. Seiler | P. C. Lucas